PT Jayamas Medica Industri Tbk

As of June 30, 2026, PT Jayamas Medica Industri Tbk carries a market capitalization of 5.56T, placing it among publicly traded companies globally. Its enterprise value stands at 4.44T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PT Jayamas Medica Industri Tbk's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, PT Jayamas Medica Industri Tbk has 27.01B shares outstanding.

As of June 30, 2026, PT Jayamas Medica Industri Tbk trades at a trailing price-to-earnings ratio of 13.47. The price-to-sales ratio is 2.47, and the price-to-book ratio stands at 1.97.

As of June 30, 2026, PT Jayamas Medica Industri Tbk trades at an EV/EBITDA multiple of 9.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.44T versus a market cap of 5.56T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Jayamas Medica Industri Tbk maintains a current ratio of 8.29, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.17, indicating elevated leverage, while an interest coverage ratio of 23.59 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Jayamas Medica Industri Tbk posted a return on equity (ROE) of 15.41, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.57 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.45, useful for judging operating efficiency across full business cycles. The company generates approximately 1.87B in revenue per employee across its workforce of 1,203.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.10 indicates how many times PT Jayamas Medica Industri Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Jayamas Medica Industri Tbk recorded 101.06B in income tax expense. That works out to an effective tax rate of 19.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 517.32B, leaving 413.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PT Jayamas Medica Industri Tbk's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 221.82, while the 200-day moving average is 228.55.

Over the twelve months ended June 30, 2026, PT Jayamas Medica Industri Tbk generated 2.25T in revenue and converted that into 413.15B in net income, yielding earnings per share of 15.40. EBITDA reached 450.56B, while operating income came in at 449.52B.

As of June 30, 2026, PT Jayamas Medica Industri Tbk holds 1.42T in cash and equivalents against 262.64B in total debt, resulting in a net debt position of -1.08T. Total book value stands at 2.83T, with working capital of 2.23T providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Jayamas Medica Industri Tbk posted a gross margin of 35.75, reflecting its pricing power and cost economics. The operating margin of 19.98 and net profit margin of 18.36 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, PT Jayamas Medica Industri Tbk paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PT Jayamas Medica Industri Tbk shareholders.

As of June 30, 2026, PT Jayamas Medica Industri Tbk has an Altman Z-Score of 8.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.